377 related articles for article (PubMed ID: 27914004)
1. Hybrid Receptor-Bound/MM-GBSA-Per-residue Energy-Based Pharmacophore Modelling: Enhanced Approach for Identification of Selective LTA4H Inhibitors as Potential Anti-inflammatory Drugs.
Appiah-Kubi P; Soliman M
Cell Biochem Biophys; 2017 Mar; 75(1):35-48. PubMed ID: 27914004
[TBL] [Abstract][Full Text] [Related]
2. Dual anti-inflammatory and selective inhibition mechanism of leukotriene A4 hydrolase/aminopeptidase: insights from comparative molecular dynamics and binding free energy analyses.
Appiah-Kubi P; Soliman ME
J Biomol Struct Dyn; 2016 Nov; 34(11):2418-33. PubMed ID: 26555301
[TBL] [Abstract][Full Text] [Related]
3. Identification of Human Leukotriene A4 Hydrolase Inhibitors Using Structure-Based Pharmacophore Modeling and Molecular Docking.
Audat SA; Al-Shar'i NA; Al-Oudat BA; Bryant-Friedrich A; Bedi MF; Zayed AL; Al-Balas QA
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580506
[TBL] [Abstract][Full Text] [Related]
4. Binding of Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and development of an epoxide hydrolase selective inhibitor.
Stsiapanava A; Olsson U; Wan M; Kleinschmidt T; Rutishauser D; Zubarev RA; Samuelsson B; Rinaldo-Matthis A; Haeggström JZ
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4227-32. PubMed ID: 24591641
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and physiological relevance of designing highly potent aminopeptidase-sparing leukotriene A4 hydrolase inhibitors.
Numao S; Hasler F; Laguerre C; Srinivas H; Wack N; Jäger P; Schmid A; Osmont A; Röthlisberger P; Houguenade J; Bergsdorf C; Dawson J; Carte N; Hofmann A; Markert C; Hardaker L; Billich A; Wolf RM; Penno CA; Bollbuck B; Miltz W; Röhn TA
Sci Rep; 2017 Oct; 7(1):13591. PubMed ID: 29051536
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the 5-Lipoxygenase Pathway by Chalcogen-Containing Inhibitors of Leukotriene A
Teder T; König S; Singh R; Samuelsson B; Werz O; Garscha U; Haeggström JZ
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108702
[TBL] [Abstract][Full Text] [Related]
7. Thermodynamic properties of leukotriene A
Wittmann SK; Kalinowsky L; Kramer JS; Bloecher R; Knapp S; Steinhilber D; Pogoryelov D; Proschak E; Heering J
Bioorg Med Chem; 2016 Nov; 24(21):5243-5248. PubMed ID: 27651294
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.
Karami L; Saboury AA; Rezaee E; Tabatabai SA
Eur Biophys J; 2017 Jul; 46(5):445-459. PubMed ID: 27928588
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking and pharmacophore filtering in the discovery of dual-inhibitors for human leukotriene A4 hydrolase and leukotriene C4 synthase.
Thangapandian S; John S; Sakkiah S; Lee KW
J Chem Inf Model; 2011 Jan; 51(1):33-44. PubMed ID: 21133343
[TBL] [Abstract][Full Text] [Related]
10. The development of novel LTA
Low CM; Akthar S; Patel DF; Löser S; Wong CT; Jackson PL; Blalock JE; Hare SA; Lloyd CM; Snelgrove RJ
Sci Rep; 2017 Mar; 7():44449. PubMed ID: 28303931
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics simulation study and hybrid pharmacophore model development in human LTA4H inhibitor design.
Thangapandian S; John S; Arooj M; Lee KW
PLoS One; 2012; 7(4):e34593. PubMed ID: 22496831
[TBL] [Abstract][Full Text] [Related]
12. In silico modeling of the molecular structure and binding of leukotriene A4 into leukotriene A4 hydrolase.
Paz PB; Vega-Hissi EG; Estrada MR; Garro Martinez JC
Chem Biol Drug Des; 2012 Dec; 80(6):902-8. PubMed ID: 22913921
[TBL] [Abstract][Full Text] [Related]
13. Saccharomyces cerevisiae leukotriene A4 hydrolase: formation of leukotriene B4 and identification of catalytic residues.
Kull F; Ohlson E; Lind B; Haeggström JZ
Biochemistry; 2001 Oct; 40(42):12695-703. PubMed ID: 11601994
[TBL] [Abstract][Full Text] [Related]
14. A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity.
Poras H; Duquesnoy S; Fournié-Zaluski MC; Ratinaud-Giraud C; Roques BP; Ouimet T
Anal Biochem; 2013 Oct; 441(2):152-61. PubMed ID: 23851339
[TBL] [Abstract][Full Text] [Related]
15. Capturing LTA
Stsiapanava A; Samuelsson B; Haeggström JZ
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9689-9694. PubMed ID: 28827365
[TBL] [Abstract][Full Text] [Related]
16. QSAR, docking studies and pharmacophore identification of phenylmethyl phenoxy propyl amino propanoic acid derivatives as leukotriene A4 hydrolase inhibitors.
Sonawane LV; Bari SB
Yao Xue Xue Bao; 2010 May; 45(5):615-23. PubMed ID: 20931764
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of leukotriene A4 hydrolase/aminopeptidase by captopril.
Orning L; Krivi G; Bild G; Gierse J; Aykent S; Fitzpatrick FA
J Biol Chem; 1991 Sep; 266(25):16507-11. PubMed ID: 1885582
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore-based virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors.
Thangapandian S; John S; Sakkiah S; Lee KW
Eur J Med Chem; 2011 May; 46(5):1593-603. PubMed ID: 21377770
[TBL] [Abstract][Full Text] [Related]
19. PENG: a neural gas-based approach for pharmacophore elucidation. method design, validation, and virtual screening for novel ligands of LTA4H.
Moser D; Wittmann SK; Kramer J; Blöcher R; Achenbach J; Pogoryelov D; Proschak E
J Chem Inf Model; 2015 Feb; 55(2):284-93. PubMed ID: 25625859
[TBL] [Abstract][Full Text] [Related]
20. An integrated computational approach of molecular dynamics simulations, receptor binding studies and pharmacophore mapping analysis in search of potent inhibitors against tuberculosis.
Agarwal S; Verma E; Kumar V; Lall N; Sau S; Iyer AK; Kashaw SK
J Mol Graph Model; 2018 Aug; 83():17-32. PubMed ID: 29753941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
